AbbVie Inc. (ABBV)
ABBV Price and Sentiment
ABBV Latest news
Dividend Harvesting: Week 36 Update, $3,600 Allocated, $239.30 In Annual Dividends Yielding 6.54% With 52 Positions2021-11-11 08:30
After 36 weeks and $3,600, the Dividend Harvesting Portfolio is generating $239.30 in estimated annual income and $19.94 in monthly estimated income.
In this article series, we provide a weekly summary of dividend changes. A summary table presents relevant data and key statistics of dividend increases.
AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 20252021-11-10 08:30
NORTH CHICAGO, Ill. and CHICAGO, Nov. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and the University of Chicago and have extended their collaboration agreement through 2025 to support preclinical oncology research.
NORTH CHICAGO, Ill., Nov. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Wednesday, November 17, 2021.
Dividend Income Summary: Bert's October 2021 Report
AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 20212021-11-09 08:45
NORTH CHICAGO, Ill., Nov. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from new post-hoc analyses from the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 trials assessing the efficacy of upadacitinib (RINVOQ®) on axial symptoms in adult patients with active psoriatic arthritis (PsA) and axial involvement.
AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis2021-11-09 08:31
NORTH CHICAGO, Ill., Nov. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new results from a post-hoc analysis of the Phase 3 SELECT-BEYOND clinical trial evaluating RINVOQ® (upadacitinib; 15 mg, once daily) in patients with moderate to severe rheumatoid arthritis (RA) on stable background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with prior inadequate response or intolerance to at least one biologic DMARD.
Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting2021-11-08 08:30
NORTH CHICAGO, Ill., Nov. 8, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new pooled post-hoc analyses and patient-reported outcomes (PROs) of VUITYTM (pilocarpine HCl ophthalmic solution) 1.25%, newly approved by the FDA as the first and only eye drop to treat presbyopia; additional analyses on DURYSTA® (bimatoprost intracameral implant); and three real-world data studies on the glaucoma patient journey at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting, November 12-15.
These companies could both diversify your portfolio and boost your dividend income.
No portfolio or strategy can be perfect. But can there be a strategy that can work well in a bull market, a bear market, or a stagnant market, generate a decent income, and conserve capital, all at the same time? We also want our strategy to avoid roller-coaster rides of index investing, have low volatility and limited drawdowns in case of deep corrections.